The BA.3.2 variant, commonly referred to as the Cicada variant, is a descendant of the BA.3 subvariant of Omicron that emerged in 2022. It was first identified in South Africa in November 2024 and has since been detected in over 20 countries, including 25 states in the United States. With approximately 70 to 75 mutations in its spike protein, the Cicada variant has raised concerns among health officials and the public alike.

Initial reports indicate that common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those of previous COVID-19 strains, particularly the Omicron variants.

Despite the presence of these symptoms, current evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier variants. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” Most cases appear to be mild to moderate, resembling flu-like illness, especially among vaccinated individuals.

Health experts emphasize that the current COVID-19 vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. However, there are concerns regarding the variant’s multiple mutations, which may impact vaccine effectiveness. Observers note that while the vaccines may not be as effective against the Cicada variant, they still offer significant protection against severe outcomes.

The Cicada variant primarily spreads through respiratory droplets and close contact in crowded or poorly ventilated spaces, similar to other COVID-19 variants. Health authorities are actively monitoring its rise, particularly in the United States, where cases are currently increasing.

Health experts recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the spread of the virus. As the situation develops, health officials continue to assess the variant’s impact and provide guidance to the public.

In summary, the symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains, and there is no strong evidence suggesting increased severity of illness caused by this variant. Most cases remain mild and can be managed at home with rest and hydration. Details remain unconfirmed as health authorities continue to gather data on this emerging variant.

The post Cicada COVID Variant Symptoms appeared first on newscri.

The Cicada COVID-19 variant, classified as BA.3.2 and part of the Omicron family, has emerged as a significant concern in India. This variant was first identified in South Africa in November 2024 and has since been detected in over 22 countries.

As of now, the Cicada variant carries approximately 75 mutations, with more than 50 of these located in the spike protein. This extensive mutation profile raises questions about its potential to evade immunity from previous infections or vaccinations.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. However, it is important to note that the Cicada variant has not been confirmed to cause more severe illness compared to earlier variants.

The first confirmed case of the Cicada variant in the United States was reported in June 2025, and by January 2026, three patients had been confirmed, all of whom recovered. This variant’s spread is being closely monitored by health authorities.

Dr. Robert Hopkins Jr. stated, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This highlights the uncertainty surrounding the variant’s impact and prevalence.

The Centers for Disease Control and Prevention (CDC) emphasized the importance of monitoring the spread of BA.3.2, noting that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity.

As the situation develops, health officials in India and around the world are on high alert. The emergence of the Cicada variant underscores the ongoing challenges posed by COVID-19 and its evolving strains.

Details remain unconfirmed regarding the full extent of the variant’s impact and its implications for public health. Continued vigilance and research are essential as the global community navigates this new phase of the pandemic.

The post Cicada COVID Variant in India: Latest Developments appeared first on newscri.